Sirolimus for the treatment of complicated vascular anomalies in children
Cincinnati Children's Hospital Medical Center · University of Cincinnati · +1 more institution
Abstract
Vascular anomalies comprise a diverse group of diagnoses. While infantile hemangiomas are common, the majority of these conditions are quite rare and have not been widely studied. Some of these lesions, though benign, can impair vital structures, be deforming, or even become life-threatening. Vascular tumors such as kaposiform hemangioendotheliomas (KHE) and complicated vascular malformations have proven particularly difficult to treat. PROCEDURE: Here we retrospectively evaluate a series of six patients with complicated, life-threatening vascular anomalies who were treated with the mTOR inhibitor sirolimus for compassionate use at two centers after failing multiple other therapies.
These patients showed significant improvement in clinical status with tolerable side effects.
Citation impact
- FWCI
- 22.52
- Percentile
- 100%
- References
- 42
Authors
9- AMAdrienne M. HammillCorresponding
Cincinnati Children's Hospital Medical Center, University of Cincinnati
- MWMarySue Wentzel
Cincinnati Children's Hospital Medical Center
- AGAnita Gupta
Cincinnati Children's Hospital Medical Center, University of Cincinnati
- SCStephen C. Nelson
Children’s Minnesota - St. Paul Hospital
- AWAnne W. Lucky
Cincinnati Children's Hospital Medical Center, University of Cincinnati
Topics & keywords
- Medicine
- Sirolimus
- Discovery and development of mTOR inhibitors
- Blood cancer
- Vascular Tumors
- Vascular anomaly
- Vascular malformation
- Hemangioma
- Good health and well-being